Peptable

Comparison

CJC-1295 vs TB-500

Function

While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, TB-500 is studied for enhancing musculoskeletal and cardiac repair, wound healing, and promoting cell migration and differentiation via actin cytoskeleton remodeling21255.

Mechanism

While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, TB-500 is a synthetic peptide comprising the LKKTETQ actin-binding motif of thymosin beta-4 that binds G-actin, sequesters actin monomers, and promotes cell migration, angiogenesis, and tissue repair1255.

Receptor

CJC-1295

Growth hormone–releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs1094103

TB-500

Binds monomeric actin (G-actin) rather than a classical cell-surface receptor, modulating actin polymerization at barbed and pointed ends55

Organism or Origin

CJC-1295

Synthetic peptide based on human hypothalamic GHRH10120

TB-500

Synthetic derivative of human thymosin beta-4, whose full-length 43-amino-acid protein is abundant in mammalian tissues21279

Gene

CJC-1295

GHRH

TB-500

TMSB4X

Summary

CJC-1295 and TB-500 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: CJC-1295 is more often discussed in the realm of Metabolic and endocrine and Aging and longevity, whereas TB-500 is more often associated with the realm of Musculoskeletal health and Cardiovascular health. Their biological logic is quite different: CJC-1295 is a receptor agonist and a hormone analog, whereas TB-500 is a signaling modulator and a growth factor mimetic. Both are synthetic in origin and both are still best understood as being in Preclinical development. CJC-1295 takes the form of a peptide conjugate, whereas TB-500 is closer to a linear peptide, CJC-1295 incorporates d-amino acid substitution features that are not part of TB-500; while their sequence patterns also diverge, with CJC-1295 showing alpha-helical domain features and TB-500 showing protein-mimetic sequence features.

Sources

10CJC-1295: Long-Acting GHRH Analog - Alpha Carbon Labs, https://alphacarbonlabs.com/blog/cjc-1295-long-acting-ghrh-analog
82CJC-1295 no DAC 5mg (Mod GRF 1-29), https://www.peptidesciences.com/mod-grf-1-29-5mg-cjc-1295-no-dac
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone
2TB-500 (Thymosin Beta-4) | Peptide Biologix, https://peptidebiologix.com/tb-500
12Thymosin Beta-4 vs TB-500 | What to Know in 2024, https://www.peptidesciences.com/peptide-research/thymosin-beta-4-vs-tb-500
79TMSB4X Gene: Function, Research, and Clinical Applications, https://learn.mapmygenome.in/genemap/tmsb4x